Effects of Valproic Acid on Longitudinal Bone Growth

Abstract

Valproic acid is widely used in the treatment of children with epilepsy. Evidence indicates that valproic acid has teratogenic effects on the skeletal system. In addition, the use of valproic acid in children has been associated with short stature. Thus, we hypothesized that valproic acid could also affect bone growth after skeletal morphogenesis is completed. To test this hypothesis, we cultured fetal rat metatarsal bones in the presence of valproic acid. Valproic acid markedly suppressed metatarsal longitudinal growth. To determine the underlying mechanisms, we studied cell proliferation and hypertrophy in the growth plate, the site where bone growth takes place. At the end of the culture period, valproic acid—treated bones exhibited narrow growth plate proliferative and hypertrophic zones and an expanded ossification center. In addition, valproic acid suppressed chondrocyte proliferation in the metatarsal rudiments. Our results suggest that valproic acid suppresses longitudinal bone growth by inhibiting cartilage formation and accelerating ossification of the growth plate. These findings warrant a prospective study on the effects of valproic acid on growth in children treated with valproic acid. (J Child Neurol 2004;19:26—30).

Get full access to this article

View all access options for this article.

References

Shinnar S. , Pellock JM : Update on the epidemiology and prognosis of pediatric epilepsy, review . J Child Neurol 2002;17(Suppl 1): S4—S17 .

Cowan LD : The epidemiology of the epilepsies in children . Ment Retard Dev Disabil Res Rev 2002;8: 171—181 .

Sklanchikova G. , Berezin V. , Bock E. : Valproic acid, but not its non-teratogenic analogue 2-isopropylpentanoic acid, affects proliferation, viability and neuronal differentiation of the human teratocarcinoma cell line Ntera-2 . Neurotoxicology 1998;19: 357-370 .

Christianson AL , Checler N. , Kromberg JG : Fetal valproate syndrome: Clinical and neuro-developmental features in two sibling pairs . Dev Med Child Neurol 1993;36: 361—369 .

Kao J. , Brown NA , Schmid B. , et al: Teratogenicity of valproic acid: in vivo and in vitro investigations . Teratogen Carcinogen Mutagen 1981;1: 367—382 .

Nau H. , Hendrickx AG : Valproic teratogenesis. ISI Atlas of Science . Pharmacology 1987;1: 52—56 .

Vorhees CV : Behavioral teratogenicity of valproic acid: Selective effects on behavior after prenatal exposure to rats . Psychopharmacology (Berl) 1987;92: 173—179 .

Chrsis D. , Ritzen EM , Savendahl L. : Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes . J Endocrinol 2003; 76: 331—337 .

Wang W. , Xu JP , Kirsch T. : Annexin-mediated Ca2+ influx regulates growth plate chondrocyte maturation and apoptosis . J Biol Chem 2003;278: 3762—3769 .

10.

Knupfer MM , Pulzer F. , Schindler I. , et al; Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro . Anticancer Res 2001;21: 347—351 .

11.

Cinatl J. Jr, Cinatl J. , Driever PH , et al: Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Antiancer Drugs 1997;8: 958—963 .

12.

Bittigau P. , Sifringer M. , Genz K. , et al: Antiepileptic drugs and apoptotic neurodegeneration in the developing brain . Proc Natl Acad Sci U S A 2002;99: 15089—15094 .

13.

Kawagoe R. , Kawagoe H. , Sano K. : Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways . Leuk Res 2002;26: 495—502 .

14.

Menegola E. , Broccia ML , Prati M. , Giavini E. : Stage-dependent skeletal malformations induced by valproic acid in rat . Int J Dev Biol 1998 ;42: 99—102 .

15.

Menegola E. , Broccia ML , Nau H. , et al: Teratogenic effects of sodium valproate in mice and rats at midgestation and at term . Teratog Carcinog Mutagen 1996;16: 97—108 .

16.

Basu A. , Wezeman FH : Developmental toxicity of valproic acid during embryonic chick vertebral chondrogenesis . Spine 2000; 25: 2158—2164 .

17.

Robinson PB , Harris M. , Harvey W. , Papadogeorgakis N. : Reduced bone growth in rats treated with anticonvulsant drugs: a type II pseudohypoparathyroidism? Metab Bone Dis Relat Res 1982;4: 269—275 .

18.

Robinson PB , Harvey W. , Belal MS : Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate . Br J Exp Pathol 1988;69: 17—22 .

19.

Snyder PJ , Badura LL : Chronic administration of sodium valproic acid slows pubertal maturation in inbred DBA/2J mice: skeletal, histological, and endocrinological evidence . Epilepsy Res 1995; 20: 203—211 .

20.

Guo CY , Ronen GM , Atkinson SA : Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy . Epilepsia 2001;42: 1141—1147 .

21.

Rattya J. , Vainionpaa L. , Knip M. , et al: The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy . Pediatrics 1999;103: 588—593 .

22.

Verrotti A. , Basciani F. , De Simone M , et al: Insulin resistance in epileptic girls who gain weight after therapy with valproic acid . J Child Neurol 2002;17: 265—268 .

23.

Demir E. , Aysun S. : Weight gain associated with valproate in childhood . Pediatr Neurol 2000;22: 361—364 .